06669 ACOTEC-B
- 6.180
- -0.080-1.28%
ACOTEC-B News
先瑞達醫療-B：2023年報
Xianruida Medical-B (06669): Application for registration of coronary hypertension balloon dilatation catheter pterygium was approved by China Drug Administration
Xianruida Medical-B (06669) issued an announcement. On March 20, 2024, the Group received China's national pharmaceuticals...
Xianruida Medical-B (06669.HK)'s annual adjusted net profit of $42.435 million increased 22.1% year-on-year
On March 25, Gelonghui | Xianruida Medical-B (06669.HK) issued an announcement. The stable and favorable state of production and research directly led to a rapid increase in annual revenue. For the year ended 31 December 2023, the company's revenue was approximately RMB 473.8 million, an increase of approximately 19.8% over the previous year. The company's core products, AcoArt Orchid & Dhalia and AcoArt Tulip & Litos, became the company's core revenue sources. The adjusted net profit during the year was $42.435 million, an increase of 22.1% over the previous year. Group as of 202312
ACOTEC-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Xianruida Medical-B (06669.HK) held a board meeting on March 25 to consider and approve the annual results
Glonghui, March 13 | Xianruida Medical-B (06669.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the audited annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider payment of a final dividend (if any).
Acotec Scientific's Peridge Catheter Gets China Approval
Acotec Scientific Holdings (HKG:6669) obtained registration approval from China's National Medical Products Administration for Peridge, a peripheral scoring balloon dilatation catheter. The device is
Selected Announcements | New Oriental and Yu Minhong promised to purchase a total of HK$700 million Dongfang Selected Shares; Yao Ming Joint Inc. expects adjusted net profit to increase by more than 100% last year
Saisheng Pharmaceutical: The Phase III clinical trial of Vaborem® in China completed the enrollment of all subjects; Xianruida Healthcare: The registration application for PERIDGE® was approved by the China National Drug Administration.
Xianruida Medical-B (06669.HK): PERIDGE registration application approved by the State Drug Administration
Gelonghui January 31 | Xianruida Medical-B (06669.HK) issued an announcement. On January 30, 2024, the company received approval from the China National Drug Administration to register Peridge, a balloon expansion catheter with peripheral incision. This product is suitable for the treatment of occlusive lesions of autologous or synthetic arteriovenous fistula tubes used for hemodialysis. Peridge can provide an effective fixed focus point, which helps the plaque to open in a targeted manner. While expanding the lumen, it reduces the incidence and severity of elastic contraction of plaques or proliferative endometrial tissue and blood flow restrictive dissection, reduces excessive damage to blood vessels, and can be used as medicine
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Selected Announcements｜Alibaba Pictures completed the share acquisition of Damai.com; MODERN DENTAL's revenue for the first three quarters increased by about 13% year-on-year to HK$2,363 billion
PhysicsHealth plans to acquire 42.88% of Xinya's shares for HK$115 million to promote the expansion of the medical laboratory testing market; on November 30, Tencent Holdings spent HK$400 million to repurchase 1.24 million shares.
Xianruida Healthcare-B (06669): Japan's Ministry of Health, Labor, and Welfare approves VERICOR
Xianruida Medical-B (06669) announced that on September 19, 2023, the company received information from the Ministry of Health, Labor, and Welfare of Japan...
ACOTEC-B: 2023 INTERIM REPORT
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
Changes in Hong Kong stocks | Xianruida Medical-B (06669) rose more than 4%, and the company's product, the microcatheter Vericor-14, was approved by Japan and Thailand
The Zhitong Finance App learned that Xianruida Medical-B (06669) has now risen by more than 4%. As of press release, it has risen 3.91% to HK$13.3, with a turnover of HK$1,855,500. According to the news, Xianruida Medical issued an announcement. On August 25, 2023, the company's product, the microcatheter Vericor-14, obtained product registration approval from the Ministry of Health, Labor, and Welfare of Japan (registration certificate number: 30500BZI00032000). On August 30, 2023, the microcatheter Vericor-14 received registration approval from the Food and Drug Administration of Thailand (registration certificate number: 66-2-
Acotec Scientific's Microcatheter Vericor-14 Gets Registration Approval in Japan
Japan's Ministry of Health, Labour and Welfare has approved the product registration of Acotec Scientific Holdings' (HKG:6669) Microcatheter Vericor-14. The product provides support to facilitate the
ACOTEC-B: SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022
ACOTEC-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Analysis
Price Target
No Data
